B J Cusack
Overview
Explore the profile of B J Cusack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
499
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cusack B, Gambliel H, Musser B, Hadjokas N, Shadle S, Charlier H, et al.
Cancer Chemother Pharmacol
. 2006 Mar;
58(4):517-26.
PMID: 16555089
Purpose: Anthracyclines, such as doxorubicin and daunorubicin, continue to be widely used in the treatment of cancer, although they share the adverse effect of chronic, cumulative dose-related cardiotoxicity. The only...
2.
Abbott B, Abbott R, Adhikari R, Ageev A, Allen B, Amin R, et al.
Phys Rev Lett
. 2005 May;
94(18):181103.
PMID: 15904354
We place direct upper limits on the amplitude of gravitational waves from 28 isolated radio pulsars by a coherent multidetector analysis of the data collected during the second science run...
3.
Olson R, Li X, Palade P, Shadle S, Mushlin P, Gambliel H, et al.
Toxicol Appl Pharmacol
. 2000 Dec;
169(2):168-76.
PMID: 11097869
Cardiac effects of anthracyclines or their metabolites may include both the stimulation and inhibition of Ca(2+) release from sarcoplasmic reticulum. In this study, the ability of daunorubicin and its primary...
4.
Shadle S, Bammel B, Cusack B, Knighton R, Olson S, Mushlin P, et al.
Biochem Pharmacol
. 2000 Oct;
60(10):1435-44.
PMID: 11020445
Anthracyclines, such as daunorubicin (Daun), and other quinone-containing compounds can stimulate the formation of toxic free radicals. The present study tests the hypothesis that the quinone moiety of Daun, by...
5.
Burke B, Gambliel H, Olson R, Bauer F, Cusack B
Br J Pharmacol
. 2000 Aug;
131(1):1-4.
PMID: 10960060
Anthracyclines can cause cumulative dose-related cardiotoxicity characterized by changes in Ca(2+) metabolism, including dysfunction of the sacroplasmic reticulum (SR) and decreased expression of Ca(2+)-handling proteins, such as the ryanodine receptor...
6.
Loi C, Parker B, Cusack B, Vestal R
J Pharmacol Exp Ther
. 1997 Feb;
280(2):627-37.
PMID: 9023273
The individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism were examined in healthy young and elderly male and female nonsmokers. Single-dose studies of theophylline pharmacokinetics were performed...
7.
Cusack B, Young S, Vestal R, Olson R
Cancer Chemother Pharmacol
. 1997 Jan;
39(6):505-12.
PMID: 9118462
Age-related differences in pharmacokinetics may be important in determining altered anthracycline cardiotoxicity in the senescent rat and also in older humans. This study examined the effect of aging on daunorubicin...
8.
Cusack B, Mushlin P, Johnson C, Vestal R, Olson R
J Gerontol A Biol Sci Med Sci
. 1996 Sep;
51(5):B376-84.
PMID: 8808986
This study examined effects of aging on the cardiac response in vitro to daunorubicin, a cancer chemotherapeutic agent that causes cardiotoxicity. Left ventricular trabeculae carneae from adult (aged 6-9 months)...
9.
Parker B, Cusack B, Vestal R
Drugs Aging
. 1995 Jul;
7(1):10-8.
PMID: 7579777
With increasing age, there are a number of physiological changes that affect the handling of drugs in the human body. Increases in body fat percentage as well as decreases in...
10.
Cusack B, Young S, Olson R
Cancer Chemother Pharmacol
. 1995 Jan;
35(3):213-8.
PMID: 7805179
Recent evidence suggests that 13-hydroxy metabolites of anthracyclines may contribute to cardiotoxicity. This study was designed to determine the pharmacokinetics of daunorubicin and the 13-hydroxy metabolite daunorubicinol in plasma and...